Taken together, these data suggested that CD8+T cell infiltration was impeded by PGRN-induced CD8+T cells exhaustion which impaired the effectiveness of anti-PD-1 therapy, and restoration of CD8+T cell infiltration via PGRN depletion/inhibition was a prerequisite for effective anti-PD-1 therapy in the breast cancer. This evidence concerns the gene PDCD1 and breast carcinoma.